With The positive result of the first phase III study, coupled with the positive responses of nurses and patients, AcelRx Pharmaceuticals (ACRX) saw a substantial increase in its share price, reaching a high of $5.19 in late November. As is often…
With The positive result of the first phase III study, coupled with the positive responses of nurses and patients, AcelRx Pharmaceuticals (ACRX) saw a substantial increase in its share price, reaching a high of $5.19 in late November. As is often…
